Gain Therapeutics Reports Positive Phase 1b Extension Data for Rexaceract

Gain Therapeutics presented positive Phase 1b open-label extension data for its drug rexaceract. The data, collected over 12 months, showed stability in MDS-UPDRS motor scores from baseline in 12 evaluable participants.